S8 Ep14: Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

from OncLive® On Air · host OncLive® On Air

Dr Hilal discusses data with frontline ibrutinib, acalabrutinib, and zanubrutinib in chronic lymphocytic leukemia; remaining uncertainties regarding the use of BTK inhibitors to manage this disease; and how a patient’s minimal residual disease status influences their subsequent treatment options.

Episode metadata supplied by the publisher feed · Published Jan 12, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

S8 Ep14: Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

0:00 12:18

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 12 minutes long.

When was this OncLive® On Air episode published?

This episode was published on January 12, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!